ThromboGenics NV, a biopharmaceutical company developing novel medicines for back of the eye disease, announced that the protocol of the phase II CIRCLE trial evaluating multiple doses of THR-409 to induce a total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy (NPDR) has been amended.

The changes will allow inclusion of patients with less severe non-proliferative diabetic retinopathy (ETDRS level 43A - 47A). This will result in a broader patient pool for the study to recruit from.

The amended study, which focuses on assessing the ability of multiple doses of THR-409 to induce a total PVD in patients with NPDR, is now expected to enroll approximately 115 patients.

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.